| Schedule of intangible assets amortization expense |
| | |
June 30, 2022 | | |
December 31, 2021 | |
| | |
Gross Carrying Amount | | |
Accumulated Amortization | | |
Net Carrying Amount | | |
Gross Carrying Amount | | |
Accumulated Amortization | | |
Net Carrying Amount | |
| Krillase intangible assets | |
$ | 28,600,000 | | |
$ | - | | |
$ | 28,600,000 | | |
$ | 28,600,000 | | |
$ | - | | |
$ | 28,600,000 | |
| Patents in process | |
| 122,745 | | |
| - | | |
| 122,745 | | |
| 122,745 | | |
| - | | |
| 122,745 | |
| DuraGraft patent | |
| 5,256,000 | | |
| (774,922 | ) | |
| 4,481,078 | | |
| 5,256,000 | | |
| (572,768 | ) | |
| 4,683,232 | |
| Duragraft - Distributor relationship | |
| 308,000 | | |
| (59,033 | ) | |
| 248,967 | | |
| 308,000 | | |
| (43,633 | ) | |
| 264,367 | |
| Duragraft IPR&D - Cyto Protectant Life Sciences | |
| 12,606,000 | | |
| - | | |
| 12,606,000 | | |
| 12,606,000 | | |
| - | | |
| 12,606,000 | |
| My Health Logic - Trade name | |
| 450,000 | | |
| (16,875 | ) | |
| 433,125 | | |
| 450,000 | | |
| (804 | ) | |
| 449,196 | |
| My Health Logic - Biotechnology | |
| 4,600,000 | | |
| (142,059 | ) | |
| 4,457,941 | | |
| 4,600,000 | | |
| (6,765 | ) | |
| 4,593,235 | |
| My Health Logic - Software | |
| 1,550,000 | | |
| (54,250 | ) | |
| 1,495,750 | | |
| 1,550,000 | | |
| (2,583 | ) | |
| 1,547,417 | |
| Total intangibles | |
$ | 53,492,745 | | |
$ | (1,047,139 | ) | |
$ | 52,445,606 | | |
$ | 53,492,745 | | |
$ | (626,553 | ) | |
$ | 52,866,192 | |
|
| Intangible
Assets | |
December 31, 2021 | | |
December 31, 2020 | |
| | |
Gross Carrying Amount | | |
Accumulated Amortization | | |
Net
Carrying Amount | | |
Gross Carrying Amount | | |
Accumulated Amortization | | |
Net
Carrying Amount | |
| Krillase intangible assets | |
$ | 28,600,000 | | |
$ | - | | |
$ | 28,600,000 | | |
$ | 28,600,000 | | |
$ | - | | |
$ | 28,600,000 | |
| Patents in process | |
| 122,745 | | |
| - | | |
| 122,745 | | |
| 119,971 | | |
| - | | |
| 119,971 | |
| DuraGraft patent | |
| 5,256,000 | | |
| (572,768 | ) | |
| 4,683,232 | | |
| 14,147,729 | | |
| (589,489 | ) | |
| 13,558,240 | |
| DuraGraft - Distributor relationship | |
| 308,000 | | |
| (43,633 | ) | |
| 264,367 | | |
| - | | |
| - | | |
| - | |
| DuraGraft IPR&D - Cyto Protectant Life Sciences | |
| 12,606,000 | | |
| - | | |
| 12,606,000 | | |
| - | | |
| - | | |
| - | |
| My Health Logic - Trade name | |
| 450,000 | | |
| (804 | ) | |
| 449,196 | | |
| - | | |
| - | | |
| - | |
| My Health Logic - Biotechnology | |
| 4,600,000 | | |
| (6,765 | ) | |
| 4,593,235 | | |
| - | | |
| - | | |
| - | |
| My Health Logic - Software | |
| 1,550,000 | | |
| (2,583 | ) | |
| 1,547,417 | | |
| - | | |
| - | | |
| - | |
| Total intangible assets | |
$ | 53,492,745 | | |
$ | (626,553 | ) | |
$ | 52,866,192 | | |
$ | 42,867,700 | | |
$ | (589,489 | ) | |
$ | 42,278,211 | |
|
| Schedule of goodwill |
| Goodwill | |
DuraGraft | | |
My Health Logic | | |
Total | |
| Balance, December 31, 2020 | |
$ | - | | |
$ | - | | |
$ | - | |
| Additions on acquisitions | |
| 5,416,000 | | |
| 1,774,656 | | |
| 7,190,656 | |
| Impairment | |
| - | | |
| - | | |
| - | |
| Balance, December 31, 2021 and June 30, 2022 | |
$ | 5,416,000 | | |
$ | 1,774,656 | | |
$ | 7,190,656 | |
|
| | |
DuraGraft | | |
My Health
Logic | | |
Total | |
| Balance, December 31, 2020 | |
$ | - | | |
$ | - | | |
$ | - | |
| Additions on acquisitions | |
| 5,416,000 | | |
| 1,774,656 | | |
| 7,190,656 | |
| Impairment | |
| - | | |
| - | | |
| - | |
| Balance, December 31, 2021 | |
$ | 5,416,000 | | |
$ | 1,774,656 | | |
$ | 7,190,656 | |
|
| Schedule of intangible assets |
| Balance, December 31, 2020 | |
$ | 42,278,211 | |
| Acquired in Somah Transaction | |
| 4,022,271 | |
| Acquired in My Health Logic Transaction | |
| 6,600,000 | |
| Additions | |
| 2,775 | |
| Amortization expense | |
| (37,065 | ) |
| Balance, December 31, 2021 | |
$ | 52,866,192 | |
| Amortization expense | |
| (420,586 | ) |
| Balance, June 30, 2022 | |
$ | 52,445,606 | |
|
| Balance, December 31, 2019 | |
$ | 28,613,000 | |
| Acquired in asset purchase agreement | |
| 14,147,729 | |
| Additions | |
| 106,971 | |
| Amortization expense | |
| (589,489 | ) |
| Balance, December 31, 2020 | |
$ | 42,278,211 | |
| Acquired in Somah Transaction1 | |
| 4,022,271 | |
| Acquired in MHL Transaction | |
| 6,600,000 | |
| Additions | |
| 2,775 | |
| Amortization expense1 | |
| (37,065 | ) |
| Balance, December 31, 2021 | |
$ | 52,866,192 | |
| 1 | To account for Somah Transaction measurement period adjustments, the Company restated the Quarterly Report on Form 10-Q for the three and six month ended June 30, 2021, originally filed on August 23, 2021. As a result of the restatement, the value of DuraGraft intangibles purchased with the Somah Transaction increased by $4,022,271 and related overestimated amortization of the intangibles decreased by $898,026 for the year ended December 31, 2021. |
|